Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?
Here is how Agilon Health (AGL) and Illumina (ILMN) have performed compared to their sector so far this year.

Agilon Health, Inc. provides healthcare solutions specifically designed for older adults, delivered through local primary care physicians throughout the United States. As ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.18 · Revenue $1.46B · 4 analysts
Est. EPS $-3.20 · Revenue $1.45B · 7 analysts
Est. EPS $-2.08 · Revenue $5.82B · 8 analysts
Est. EPS $1.76 · Revenue $1.54B · 2 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $5.9B | -2.1% | +5.2% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-405.3M | -55.8% | -40.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | -3.2% | -4080.2% | +74.9% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -7.1% | -47.2% | +10.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -6.8% | -59.2% | -43.1% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-119.0M | -67.5% | -394.5% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -2.0% | -71.2% | -379.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 29.0% | +211.2% | -20.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.02x | -19.5% | +4.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $1.3B | -26.7% | +5.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -24.50 vs -19.53 | -25.4% | 1.04 vs -1.18 | +188.1% |
| Revenue Surprise | $5.9B vs $5.8B | +1.9% | $1.5B vs $1.5B | +2.7% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 16, 2026 | Gertsch Timothy | officer: Chief Accounting Officer | Common Stock | D | 17 | $96.90 |
| Aug 1, 2026 | Zamore Denise | officer: Chief Legal Officer | Common Stock | D | 37 | $91.61 |
| Jul 1, 2026 | Schwaneke Jeffrey A. | officer: Chief Financial Officer | Common Stock | D | 2,311 | $111.74 |
| Jun 2, 2026 | Wulf John William | director | Common Stock | A | 2,133 | — |
| Jun 2, 2026 | WILLIAMS RONALD A | director | Common Stock | A | 2,133 | — |
Operator: Hello, everyone. Thank you for joining us and welcome to the Agilon Health Second Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question-and-answer session. [Operator Instructions] I will now hand the conference over to Evan Smith, Senior Vice President, Investor Relations. Evan, please go ahead. Evan Smith: Thank you, operator. Good afternoon, and welcome to the call. With me are our CEO, Tim O'Rourke, and our CFO, Jeff Schwaneke. Following our prepared remarks, we will conduct a Q&A session. Before we begin, I would like to remind you that our remarks and responses to questions may include forward-looking statements. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with our business. These risks and uncertainties are discussed in our SEC filings. Please note that we assume no obligation to update any forward-looking statements. Additionally, certain financial measures, which we will discuss in this call, are non-GAAP financial measures. Non-GAAP measures are supplemental and not a substitute for GAAP results. However, we believe that providing these non-GAAP measures helps investors gain a better and more complete understanding of our financial results and are consistent with how management views our financial results. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is available in the earnings press release and Form 8-K filed with the SEC today. And with that, let me turn the call over to Tim. Timothy O’Rourke: Good afternoon, everyone, and thank you for joining us today. For those I have not yet had the opportunity to meet, I'm Tim O'Rourke. I joined Agilon as Chief Executive Officer in early May. Over the past 90 days, I have met with nearly all of our physician partners, shadowed PCPs, and have witnessed firsthand how we can help and continue to improve how they care for their patients. Their passion and caring reinforces our mission at Agilon, the proximity and durability of our physician partnerships, and our absolute responsibility to support these physicians in their work across all of our communities. I have been engaged in good discussions with our payer partners and have engaged with the Agilon team. I am listening, learning, and focusing on key areas to drive additional value for all of our stakeholders. I came to Agilon because I believe it sits at the center of where value-based care is going. By partnering with community-based primary care physicians and providing them with enhanced economics, technology, and clinical tools, we enable PCPs to focus on what they are trained to do, keeping patients healthy. To further our mission, Agilon continues to advance new clinical, quality, and AI initiatives that will build upon our historical success in delivering improved patient outcomes while reducing unnecessary medical costs. We believe our collaboration with and …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Jeffrey Alan Schwaneke | Executive Vice President & Chief Financial Officer | USD 910,875 | Male | 1976 | Active |
Benjamin Shaker | Chief Markets Officer | USD 657,545 | Male | 1983 | Active |
Denise Zamore | Chief Legal Officer & Secretary | USD 623,408 | Female | 1975 | Active |
Girish Venkatachaliah | Advisor | USD 618,579 | Male | 1974 | Active |
Leland Thomas | Senior Manager of Investor Relations | — | — | — | Active |
Karthik Rao | Chief Medical Officer | — | — | — | Active |
Kenny Bellendir | Markets Chief Financial Officer | — | Male | — | Active |
Timothy Gertsch | Chief Accounting Officer | — | Male | 1987 | Active |
Evan Smith | Senior Vice President of Investor Relations | — | Male | — | Active |
Timothy Patrick O'Rourke | CEO & Director | — | Male | — | Active |
Heidi Hittner | Chief Business Operations Officer | — | Female | — | Active |
Bill Farry | Chief of Technology Innovation | — | Male | — | Active |
Here is how Agilon Health (AGL) and Illumina (ILMN) have performed compared to their sector so far this year.

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will now participate in a fireside chat at the 2026 Jefferies Healthcare Services and Technology Conference at 4:00pm ET on Monday, September 14, 2026. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the “Events & Presentations” section o.

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will participate in a fireside chat at the following conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. 2026 Jefferies Healthcare Services and Technology Conference on Monday, September 14, 2026. A live webcast will be available on the company's investor relati.

Here is how Agilon Health (AGL) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

Australian power producer AGL Energy reported a nearly 2% fall in its annual underlying profit on Wednesday, pressured by higher gas supply costs and lower wholesale electricity prices.
